These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2153234)

  • 21. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide.
    Drew MD; Estrada-Correa A; Underdown BJ; McDermott MR
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2357-66. PubMed ID: 1383408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.
    Eisenberg RJ; Cerini CP; Heilman CJ; Joseph AD; Dietzschold B; Golub E; Long D; Ponce de Leon M; Cohen GH
    J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody and cell-mediated immunity to a DNA free herpes simplex subunit vaccine.
    Cappel R; de Cuyper F; de Braekeleer J
    Dev Biol Stand; 1979; 43():381-5. PubMed ID: 230114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein.
    Jan LR; Yang CS; Henchal LS; Sumiyoshi H; Summers PL; Dubois DR; Lai CJ
    Am J Trop Med Hyg; 1993 Mar; 48(3):412-23. PubMed ID: 8385887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.
    Watari E; Dietzschold B; Szokan G; Heber-Katz E
    J Exp Med; 1987 Feb; 165(2):459-70. PubMed ID: 3029270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice.
    Zhou Y; Wang Z; Xu Y; Zhang Z; Hua R; Liu W; Jiang C; Chen Y; Yang W; Kong W
    Viral Immunol; 2017 Oct; 30(8):601-614. PubMed ID: 28650722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of synthetic peptides to map the antigenic determinants of glycoprotein D of herpes simplex virus.
    Strynadka NC; Redmond MJ; Parker JM; Scraba DG; Hodges RS
    J Virol; 1988 Sep; 62(9):3474-83. PubMed ID: 2457115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
    Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
    J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
    BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
    J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity.
    Ludewig B; Barchiesi F; Pericin M; Zinkernagel RM; Hengartner H; Schwendener RA
    Vaccine; 2000 Aug; 19(1):23-32. PubMed ID: 10924783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological properties of multiple repeats of a linear epitope of herpes simplex virus type 1 glycoprotein D.
    Van der Ploeg JR; Drijfhout JW; Feijlbrief M; Bloemhoff W; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(2):211-7. PubMed ID: 2480978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.